The study, sponsored by University Hospital, Clermont-Ferrand, investigates the effects of two established acetylcholinesterase inhibitors, Galantamine and Donepezil, on sleep quality in Alzheimer's patients aged 65 and older. Given the increasing prevalence of Alzheimer's disease and associated sleep disturbances, this research could provide valuable insights into adjunctive therapies that improve patient quality of life. The collaboration with Janssen-Cilag indicates potential industry interest, which may enhance the commercial viability of findings. The market for Alzheimer's therapies is significant, with a growing demand for treatments that address comorbid conditions such as sleep disorders. However, the competitive landscape includes numerous existing therapies, necessitating a clear differentiation of benefits from this study.